LY4050784 + pembrolizumab

LY4050784 + pembrolizumab is a **combination therapy** being developed for cancer treatment, specifically targeting **SMARCA4-mutant tumors** such as non-small cell lung cancer (NSCLC). LY4050784 is a **selective SMARCA2 inhibitor**, working via synthetic lethality to induce tumor cell death while sparing healthy cells. Pembrolizumab is a monoclonal antibody that acts as an immune checkpoint inhibitor targeting programmed cell death protein 1 (PD-1), thereby enhancing anti-tumor immune response. Preclinical studies have demonstrated that LY4050784 sensitizes tumor cells to pembrolizumab, resulting in **enhanced and synergistic antitumor activity** compared to monotherapies. The combination is currently being assessed in Phase 1 clinical trials, with early data showing promising efficacy in SMARCA4-mutant NSCLC xenograft models[1][3][5][7].